|
|
Health Technology Assessment World Europe 2008
Pre-conference workshop
9 Dec 9am - 5pm
Day 1
10 Dec 8:30am - 5:30pm
Day 2
11 Dec 8:30am - 5:30pm
Venue
The Grosvenor Hotel
101 Buckingham Palace Rd
London, UK
|
|
|
|
Vice President, Global Health Outcomes,
Eli Lilly & Co
Marc L. Berger, M.D. is Vice President, Global Health Outcomes at Eli Lilly and Company. In this role, he has consolidated health outcomes functions across Lilly into a single organization whose mission is to provide expertise and scientific information that enables Lilly to develop and provide products that deliver better patient outcomes and are valued by payers and providers. A native of New York, he joined Lilly in April 2007 after retiring from Merck & Co., Inc. where he held the position of Vice President, Outcomes Research and Management.
He holds an M.D. degree from Johns Hopkins University School of Medicine and has adjunct appointments as Senior Fellow at the Leonard Davis Institute at the Wharton School of the University of Pennsylvania and Professor in the Department of Health Policy and Administration at the University of North Carolina at Chapel Hill School of Public Health. He also serves on the Medicare Evidence Development & Coverage Advisory Committee (MedCAC) for the Center for Medicare & Medicaid Services (CMS), the evidence-based medicine advisory committee for the National Pharmaceutical Council (NPC), and the editorial advisory board of Value in Health. In addition, he recently completed his term on the steering committee for the Agency for Health Care Research and Quality (AHRQ) Centers for Research and Education on Therapeutics (CERTs). He has published widely in peer-reviewed journals in health services research, outcomes research, health economics, and health policy.
|
|
Director of Health Economics,
GlaxoSmithKline
Isabelle Durand-Zaleski trained as an MD in Paris and holds a master's degree from Harvard University and a PhD in economics from PAris University. She is currently Professor of Medicine at the University of Paris and head of the Public Health department at Henri Mondor hospital, Paris, France
|
|
Dr Oriol de Solà-Morales, Director General,
CAHTAR
Mr. Solà-Morales was born in 1970. Having obtained his degree in Medicine and Surgery at the Universitat Autònoma de Barcelona in 1994, he did a master in "Policy, Planification and Financing Health System" at the London School of Economics and Political Science (LSE). Furthermore, he has been working for some years as a manager of Sant Joan de Déu-Aragó Hospital Area in Barcelona (Spain). Nowadays he is working as a general director in the Catalan Agency for Health Technology Assessment and Research (CAHTA).
|
|
Senior Policy Advisor,
CVZ
|
|
Professor of Health Economics,
Centre for Health Economics, University of York
Michael Drummond BSc, MCom, DPhil is Professor of Health Economics and former Director of the Centre for Health Economics at the University of York. His particular field of interest is in the economic evaluation of health care treatments and programmes. He has undertaken evaluations in a wide range of medical fields including care of the elderly, neonatal intensive care, immunization programmes, services for people with AIDS, eye health care and pharmaceuticals. He is the author of two major textbooks and more than 500 scientific papers, has acted as a consultant to the World Health Organization and was Project Leader of a European Union Project on the Methodology of Economic Appraisal of Health Technology. He has been President of the International Society of Technology Assessment in Health Care, and the International Society for Pharmacoeconomics and Outcomes Research. He is currently a member of the Guidelines Review Panels of the National Institute for Health and Clinical Excellence (NICE) in the UK, and is a Principal Consultant for i3Innovus.
|
|
Professor Isabelle Durand-Zaleski, Chief of Public Health,
Henri Mondor Hospital
|
|
Director, Market Access Solutions,
Bridgehead International
Jim Furniss is Director of Pricing and Reimbursement at Bridgehead International. He has a detailed understanding of pharmaceutical policy, pricing and market access issues throughout Europe and extensive practical experience of Company-Government relations in drug pricing and reimbursement.
Prior to moving into consultancy Jim was head of the Pharmaceutical Industry Branch in the UK Department of Health from 1991 to 1997. In this position, he was responsible for the operation of the UK Pharmaceutical Price Regulation Scheme and for the NHS drug budget for the UK. During this time he also represented the UK on pharmaceutical issues at the European Commission. He gained valuable experience in pharmaceutical price regulation across Europe as a member of the European Commission’s Pharmaceutical Pricing Transparency Committee.
Jim has spent more than 10 years in consultancy in the pharmaceutical industry, initially with Cambridge Pharma Consultancy and most recently with Bridgehead International. During this time he has worked on over 100 pharmaceutical pricing, reimbursement and market access projects, covering all major therapy areas. He has worked with all the major international pharmaceutical companies and many smaller companies. He is a regular speaker at international conferences on pharmaceutical pricing, reimbursement and market access issues.
|
|
Senior Economist,
Office of Health Economics
Adrian Towse MA, MPhil, is the Director of the Office of Health Economics.
The OHE commissions research, publications and meetings on the economics of the pharmaceutical industry, health care systems and the use of health technology assessment. It also advises the ABPI (who fund OHE) and undertakes consultancy. He is a Visiting Professor at the University of York and a Non-executive Director of the Oxford Radcliffe Hospitals NHS Trust, one of the UK’s largest hospitals. He also chairs the Health Economics Advisory Group of the International Federation of Pharmaceutical Manufacturers Associations which comprises the heads of global health outcomes of the major companies. His current research interests include the use of “risk-sharing” arrangements between health care payers and pharmaceutical companies; the economics of pharmacogenetics for health care payers and the pharmaceutical industry; economic issues around access to, and R&D for the development of, treatments for less developed country diseases; the economics of medical negligence; and measuring productivity in health care
|
|
Head,
German Agency for HTA
Dr. Britta Göhlen (PhD) is a biologist, studied health economics and was employed as a nurse. For about twenty years she as been active in the medical field as a coordinator and a project manager in areas like consulting, laboratory work and institutional research. Since 2004 she has been working at the German Agency for Health Technology Assessment at the German Institute of Medical Documentation and Information (DAHTA@DIMDI). After three years she became the head of it. Part of her duties and responsibilities are coordinating the process of the production of HTA reports, reviewing them and finding external reviewer. Dr. Göhlen has published diverse publications on different scientific topics and collaborates in different organisations (e.g. gmds, HTAi, INHATA).
|
|
Associate Director,
BlueCross Blueshield
NAOMI ARONSON, Ph.D. Dr. Aronson is the Executive Director of the Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). She has overseen TEC's development as a nationally recognized technology assessment program and an Evidence-based Practice Center (EPC) of the Agency for Healthcare Research and Quality (AHRQ). Dr. Aronson has directed over 300 technology assessments and 10 evidence reports for AHRQ. She has published articles in Annals of Internal Medicine, Journal of the National Cancer Institute, Cancer, Journal of the American College of Surgeons, Academic Radiology, Journal of Family Practice, and Gastrointestinal Endoscopy. She represented the private sector on a U.S. Agency for International Development team providing technical assistance to the Hungarian government on building evidence-based medicine capacity in the national health insurance system. She is a member of the Institute of Medicine Forum on Drug Discovery Translation and Development, and the Steering Committee of the Chicago-Area DEcIDE Research Center and the National Business Group on Health Committee on Evidence-Based Benefit Design. Previously, Dr. Aronson was a member of Northwestern University faculty, specializing in sociology of science and medicine. She was also a post-doctoral fellow in the Science, Technology and Society Program at the Massachusetts Institute of Technology and received research awards from the National Science Foundation and the American Council of Learned Societies. Dr. Aronson's academic research focused on how the organization of scientific specialties in biomedical and clinical research affects the process of scientific discovery.
|
|
Senior Lecturer in International Health Policy,
LSE Health
Dr Panos Kanavos is Senior Lecturer in International Health Policy in the Department of Social Policy and Head of the Medical Technology Research at LSE Health. He is also Visiting Professor at the University of Lausanne. He has acted as advisor to a number of international governmental and non-governmental organisations, including the World Bank, the World Health Organisation and the Organisation for Economic Co-operation and Development (OECD), the American Association for Retired Persons (AARP) and Ministries of Health in over 21 transition and developing countries. He is currently participating in the European Pharmaceutical Forum as advisor to the European Commission. His research interests comprise comparative health policy and health care reform; pharmaceutical economics and policy; quality in health care; and the socio-economic determinants of health. Panos has published extensively in the peer review literature.
|
|
Professor Fiin Borlum Kristensen, Director,
Danish Centre for Health Technology Assessment, National Board of Health
|
|
Director, Centre for Health Technology Evaulation,
NICE
Carole is Director of the Centre for Health Technology Evaluation at NICE. She has a doctorate in Pharmacology and spent 8 years at GlaxoSmithKline Research working on the development of novel pharmaceuticals. She has also undertaken many academic secondments including research at The Institute of Molecular Biology in Geneva and the University of California in Irvine, USA. Carole has previously been involved in health technology assessment as Director of the Evidence Research Unit. She contributes to a number of international policy forums, including the WHO advisory group on Priority Medical Devices and Health Technology Assessment International. Her research interests lie in the methodologies and processes of health technology assessment in the context of health policy decision making.
|
|
Director,
Swedish Council in HTA
|
|
President & CEO,
Canadian Agency for Drugs and Technologies in Health (CADTH)
|
|
Project Manager,
Double Helix Consulting
Ben Shankland is Double Helix Consulting’s Emerging Markets Lead. He joined in April 2008 from Global Insight, an emerging markets pricing and reimbursement consultancy in London. He is the author of several in-depth reports on market access issues facing the pharmaceutical industry in emerging economies. Previously he was Head of Healthcare Intelligence for Business Monitor International, an emerging markets research firm, in London. Ben holds a degree from Oxford University and is fluent in Brazilian Portuguese, Spanish and French.
|
|
Director, Global Therapeutic Head-GHO, Cardiovascular & Metabolics,
GlaxoSmithKline
|
|
Vice Chairman,
Scottish Medicines Consortium
|
|
|
|
|
|
Dr Carole Longson
Head of Technology Assessment
NICE, UK
Dr Jill Sanders
President & CEO
CADTH, Canada
 Dr Britta Göhlen Head
Germany Agency for HTA
Dr Marc L Berger
Vice President Global Health Outcomes
Eli Lilly & Company
Dr Naomi Aronson
Executive Director
Technology Evaluation Center Blue Cross BlueShield, USA
|
|
|
|
|
